A phase I study of the type II ROS1 TRK inhibitor ANS03 in ROS1 fusion-positive lung cancers

ANS-03 - Avistone Biotech

Augtyro (repotrectinib) - BMS

zidesamtinib (NVL-520) - Nuvalent

Ibtrozi (taletrectinib) - Nuvation Bio

Lorbrena (lorlatinib) - Pfizer

https://www.abstractsonline.com/pp8/#!/21436/presentation/12079

Alexander Drilon1; Jia Yu2; Zhiyong He3; Yongsheng Wang4; Kejing Tang5; Tianqing Chu2; Shutan Liao6; Junjun Zhang7; Xinlong Zheng8; Jaime Rubio-Perez9; Matteo Repetto9; Brendan Putz10; Shengxiang Ren8

Mar 18, 2026